PATENT ABSTRAC'IS 599

A family of metalloproteinases exist which cleave extracellular matrix molecules. These metalloproteinases are secreted in a latent inac- tive form and require activation in order to specifically cleave the preferred substrate. A series of peptides have been prepared based on the complete sequence analysis of type IV pro- collagenase. Peptide inhibitors were synthesized which correspond to cysteine repeat regions and histidine containing regions; the mechanism of action of these peptides involves inhibition of bi- nding of the enzyme to the substrate. Peptide in- hibitors were synthesized which correspond to the peptide cleaved off during activation, and constitute a novel class of metalloproteinase in- hibitors. These inhibitors are members of a series of peptides which contain the core amino acid sequence RKPRC or analogs thereof. The cysteine residue is required for activity. Affinity purified antibodies directed against specific pep- tides can be used to a) detect any general meta- lloproteinase enzyme with the sequence in part VAAHE or PRCGNPD, and distinguish it from other known members of the metalloproteinase family, b) block functional domains resulting in the inhibition of enzyme activity, and c) dist- inguish latent from activated forms of the en- zyme.

5280108

A N T I B O D I E S T O P 4 0

terization and pharmacological use of mammalian adrenocorticotropic hormone receptor, the gene corresponding to this recep- tor, a recombinant eukaryotic expression con- struct capable of expressing a mammalian adrenocorticotropic hormone receptor in cul- tures of transformed eukaryotic cells and such cultures of transformed eukaryotic cells that syn- thesize mammalian adrenocorticotropic hor- mone receptor. The invention also provides methods for screening ACTHR agonists and an- tagonists in vitro using preparations of receptor from such cultures of eukaryotic cells trans- formed with a recombinant eukaryotic expression construct comprising the ACTHR receptor gene. The invention specifically pro- vides human and bovine ACTHR genes.

5281416

S W I N E D Y S E N T E R Y V A C C I N E

Peter Coloe, East Doncaster, Australia assigned to Royal Melbourne Institute of Technology Limited

Method and composition for vaccination of a pig against swine dysentary caused by T. hyodysenteriae infection characterized by paren- teral, preferably intramuscular, administration to the pigs of a live strain or of an oxygen- treated, non-viable strain of T.hyodysenteriae.

Thomas G Fanning assigned to United States of America 5281417

The present invention relates, in general, to anti- bodies to p40 (both polyclonal and monoclonal). Additionally, the present invention relates to hybridomas which produce monoclonal anti- bodies to p40 and diagnostic kits comprising antibodies to p40.

5280112

D N A S E Q U E N C E E N C O D I N G B O V I N E A N D H U M A N

A D R E N O C O R T I C O T R O P I C H O R M O N E R E C E P T O R S

Roger D Cone, Kathleen G Mountjoy assigned to State of Oregon Oregon Health Sciences University

The present invention relates to a mammalian adrenocorticotropic hormone receptor. The in- vention is directed toward the isolation, charac-

A N T I T U M O R P R O C E S S E M P L O Y I N G N O V E L F E R M E N T A T E O F A N

A C T I N O M A D U R A S T R A I N

Daniel R Schroeder, Kin S Lam, Jacqueline M Veitch assigned to Bristol-Myers Squibb Com- pany

A certain fermentation product of Ac- tinomadura strain Q473-8 yields, when suitably treated, a novel compound having both anti- biotic and antitumor activities.

5281517

M E T H O D S F O R I M M U N O P L O I D Y A N A L Y S I S

James W Bacus, Robert Marder assigned to Cell Analysis Systems Inc